Featured Articles

1. EU Launches Strategic Bid to Attract R&D and Investments in Biotech 6/12/2025

   The European Union (EU) is actively courting biotech for economic growth and has launched several initiatives to attract investment and speed innovation to market, explain experts at Sidley.

2. Winning With The Right Marbles: The Future of Generics 6/11/2025

   After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO Stephen Beckman.

3. The Shift from LAL to Recombinant: What Your Lab Should Expect 6/10/2025

   Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin testing. Charles River Labs' Nicola Reid lays out the issues to consider.

4. U.S. Tariffs And Their Tenuous Impact On Clinical Trials 6/10/2025

   RSM US LLP Life Sciences Senior Analyst Amanda Laskey discusses Trump administration tariffs and how they're expected to impact the pharma world, specifically clinical research.

5. Bracing For The Impact Of The Federal Workforce Reduction 6/9/2025

   The federal workforce reductions pose significant challenges for the life sciences industry, particularly for R&D, supply chain oversight, and industry workforce development.

6. Life Sciences Business Strategies For Trump 2.0 Policy Changes 6/6/2025

   Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to enacted or anticipated policy changes under the Trump administration.

7. Winning Management Strategies For Early And Late-Stage Drug Development 6/4/2025

   Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early and late-stage drug development, explains Halloran's Carolina Ahrendt.

8. Companies To Watch: Vivani Medical 5/30/2025

   Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and possibly one full year. The company's lead program is an exenatide implant.

9. Milestone Payments: Potential Trouble In The Last Mile? 5/23/2025

   Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially when milestone payments are involved, explain experts ta Venable LLP.

10. Implications Of California's AB 824 Patent Settlement Regulation 5/21/2025

    California's AB 824 law has important implications for branded and generics companies involved in settlement agreements. AB 824 presumes, for example, that "reverse payment" agreements are illegal.